SCHEMBL2846172

SCHEMBL2846172

CC1CCCCC1(O)C=O

nearest known ligand 0.41

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.33
EPHX1 P07099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3123231 0.93
SCHEMBL11598728 0.78 MAPT (0.36) MAPT
SCHEMBL4419045 0.77 MAPT (0.35) MAPT
SCHEMBL5927006 0.76 MAPT (0.33) MAPT
SCHEMBL21114303 0.74 MAPT (0.32) MAPT
SCHEMBL21114324 0.74 MAPT (0.32) MAPT
SCHEMBL21114240 0.74 MAPT (0.32) MAPT
SCHEMBL21114334 0.74 MAPT (0.32) MAPT
SCHEMBL21114273 0.74 MAPT (0.32) MAPT
SCHEMBL21114266 0.74 MAPT (0.32) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2225302-B1 PRIMER COMPOUND CONTAINING ALDIMINE SIKA TECHNOLOGY AG (CH) 2015-04-22 EP disclosed
US-8398809-B2 Amorphous polyurethane polymer and its use in hotmelt adhesives SIKA TECHNOLOGY AG (CH) 2013-03-19 US disclosed
US-20100273924-A1 CURABLE COMPOSITIONS HAVING LESS VOLATILIZATION SIKA TECHNOLOGY AG (CH) 2010-10-28 US disclosed
EP-2225302-A1 PRIMER COMPOSITION CONTAINING ALDIMINE Sika Technology AG (CH) 2010-09-08 EP disclosed
US-20100130674-A1 METHOD FOR THE PRODUCTION OF POLYURETHANE COMPOSITIONS WITH A LOW ISOCYANATE MONOMER CONTENT SIKA TECHNOLOGY AG (CH) 2010-05-27 US disclosed
US-20100006221-A1 Amorphous polyurethane polymer and its use in hotmelt adhesives SIKA TECHNOLOGY AG (CH) 2010-01-14 US disclosed
WO-2009080731-A1 PRIMER COMPOSITION CONTAINING ALDIMINE SIKA TECHNOLOGY AG (CH) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273924-A1 CURABLE COMPOSITIONS HAVING LESS VOLATILIZATION CA4, CTH, CA6 MAPT 399/4885EPHX1 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.